GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProQR Therapeutics NV (NAS:PRQR) » Definitions » Cyclically Adjusted PB Ratio

ProQR Therapeutics NV (ProQR Therapeutics NV) Cyclically Adjusted PB Ratio : 0.68 (As of May. 24, 2024)


View and export this data going back to 2014. Start your Free Trial

What is ProQR Therapeutics NV Cyclically Adjusted PB Ratio?

As of today (2024-05-24), ProQR Therapeutics NV's current share price is $1.89. ProQR Therapeutics NV's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $2.77. ProQR Therapeutics NV's Cyclically Adjusted PB Ratio for today is 0.68.

The historical rank and industry rank for ProQR Therapeutics NV's Cyclically Adjusted PB Ratio or its related term are showing as below:

PRQR' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.42   Med: 0.68   Max: 0.92
Current: 0.7

During the past years, ProQR Therapeutics NV's highest Cyclically Adjusted PB Ratio was 0.92. The lowest was 0.42. And the median was 0.68.

PRQR's Cyclically Adjusted PB Ratio is ranked better than
70.55% of 652 companies
in the Biotechnology industry
Industry Median: 1.74 vs PRQR: 0.70

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

ProQR Therapeutics NV's adjusted book value per share data for the three months ended in Mar. 2024 was $0.463. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $2.77 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


ProQR Therapeutics NV Cyclically Adjusted PB Ratio Historical Data

The historical data trend for ProQR Therapeutics NV's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProQR Therapeutics NV Cyclically Adjusted PB Ratio Chart

ProQR Therapeutics NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.71

ProQR Therapeutics NV Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.75 0.58 0.47 0.71 0.83

Competitive Comparison of ProQR Therapeutics NV's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, ProQR Therapeutics NV's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProQR Therapeutics NV's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProQR Therapeutics NV's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where ProQR Therapeutics NV's Cyclically Adjusted PB Ratio falls into.



ProQR Therapeutics NV Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

ProQR Therapeutics NV's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.89/2.77
=0.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProQR Therapeutics NV's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, ProQR Therapeutics NV's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.463/128.5800*128.5800
=0.463

Current CPI (Mar. 2024) = 128.5800.

ProQR Therapeutics NV Quarterly Data

Book Value per Share CPI Adj_Book
201406 2.205 99.240 2.857
201409 6.140 99.960 7.898
201412 5.780 99.050 7.503
201503 5.097 99.750 6.570
201506 4.887 100.230 6.269
201509 4.597 100.500 5.881
201512 4.190 99.730 5.402
201603 3.825 100.310 4.903
201606 3.414 100.260 4.378
201609 2.953 100.570 3.775
201612 2.401 100.710 3.065
201703 2.050 101.440 2.598
201706 1.714 101.370 2.174
201709 1.533 102.030 1.932
201712 1.459 101.970 1.840
201803 1.141 102.470 1.432
201806 0.837 103.100 1.044
201809 3.092 103.950 3.825
201812 2.719 103.970 3.363
201903 2.357 105.370 2.876
201906 2.051 105.840 2.492
201909 1.694 106.700 2.041
201912 2.107 106.800 2.537
202003 1.810 106.850 2.178
202006 1.799 107.510 2.152
202009 1.612 107.880 1.921
202012 1.383 107.850 1.649
202103 1.159 108.870 1.369
202106 2.122 109.670 2.488
202109 2.126 110.790 2.467
202112 1.804 114.010 2.035
202203 1.556 119.460 1.675
202206 1.294 119.050 1.398
202209 0.900 126.890 0.912
202212 0.879 124.940 0.905
202303 0.781 124.720 0.805
202306 0.693 125.830 0.708
202309 0.609 127.160 0.616
202312 0.555 126.450 0.564
202403 0.463 128.580 0.463

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


ProQR Therapeutics NV  (NAS:PRQR) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


ProQR Therapeutics NV Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of ProQR Therapeutics NV's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ProQR Therapeutics NV (ProQR Therapeutics NV) Business Description

Traded in Other Exchanges
Address
Zernikedreef 9, Leiden, ZH, NLD, 2333 CK
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.